1420 related articles for article (PubMed ID: 16382061)
1. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
2. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
Koeberle D; Thuerlimann B
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):55-66. PubMed ID: 17912636
[TBL] [Abstract][Full Text] [Related]
3. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Forbes JF; Sestak I; Howell A; Bonanni B; Bundred N; Levy C; von Minckwitz G; Eiermann W; Neven P; Stierer M; Holcombe C; Coleman RE; Jones L; Ellis I; Cuzick J;
Lancet; 2016 Feb; 387(10021):866-73. PubMed ID: 26686313
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
Kensler KH; Regan MM; Heng YJ; Baker GM; Pyle ME; Schnitt SJ; Hazra A; Kammler R; Thürlimann B; Colleoni M; Viale G; Brown M; Tamimi RM
Breast Cancer Res; 2019 Feb; 21(1):30. PubMed ID: 30795773
[TBL] [Abstract][Full Text] [Related]
5. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Livingston RB; Davidson NE; Perez EA; Chavarri-Guerra Y; Cameron DA; Pritchard KI; Whelan T; Shepherd LE; Tu D
Ann Oncol; 2013 Feb; 24(2):355-361. PubMed ID: 23028039
[TBL] [Abstract][Full Text] [Related]
6. Safety of aromatase inhibitors in the adjuvant setting.
Perez EA
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):75-89. PubMed ID: 17912638
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Coleman R; de Boer R; Eidtmann H; Llombart A; Davidson N; Neven P; von Minckwitz G; Sleeboom HP; Forbes J; Barrios C; Frassoldati A; Campbell I; Paija O; Martin N; Modi A; Bundred N
Ann Oncol; 2013 Feb; 24(2):398-405. PubMed ID: 23047045
[TBL] [Abstract][Full Text] [Related]
8. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.
Fisher B; Costantino J; Redmond C; Poisson R; Bowman D; Couture J; Dimitrov NV; Wolmark N; Wickerham DL; Fisher ER
N Engl J Med; 1989 Feb; 320(8):479-84. PubMed ID: 2644532
[TBL] [Abstract][Full Text] [Related]
9. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV
J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
[TBL] [Abstract][Full Text] [Related]
10. Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
Mamounas EP; Bandos H; Rastogi P; Lembersky BC; Jeong JH; Geyer CE; Fehrenbacher L; Chia SK; Brufsky AM; Walshe JM; Soori GS; Dakhil SR; Wade JL; McCarron EC; Swain SM; Wolmark N
J Natl Cancer Inst; 2023 Nov; 115(11):1302-1309. PubMed ID: 37184928
[TBL] [Abstract][Full Text] [Related]
11. The patient experience.
Harbeck N; Haidinger R
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):91-103. PubMed ID: 17912639
[TBL] [Abstract][Full Text] [Related]
12. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.
Metzger Filho O; Giobbie-Hurder A; Mallon E; Gusterson B; Viale G; Winer EP; Thürlimann B; Gelber RD; Colleoni M; Ejlertsen B; Debled M; Price KN; Regan MM; Coates AS; Goldhirsch A
J Clin Oncol; 2015 Sep; 33(25):2772-9. PubMed ID: 26215945
[TBL] [Abstract][Full Text] [Related]
13. The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.
Cuzick J
Expert Rev Anticancer Ther; 2007 Aug; 7(8):1089-94. PubMed ID: 18028017
[TBL] [Abstract][Full Text] [Related]
14. Symptoms of endocrine treatment and outcome in the BIG 1-98 study.
Huober J; Cole BF; Rabaglio M; Giobbie-Hurder A; Wu J; Ejlertsen B; Bonnefoi H; Forbes JF; Neven P; Láng I; Smith I; Wardley A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Gelber RD; Thürlimann B;
Breast Cancer Res Treat; 2014 Jan; 143(1):159-69. PubMed ID: 24305979
[TBL] [Abstract][Full Text] [Related]
15. Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP.
Lazar AA; Bonetti M; Cole BF; Yip WK; Gelber RD
Clin Trials; 2016 Apr; 13(2):169-79. PubMed ID: 26493094
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
[TBL] [Abstract][Full Text] [Related]
17. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet Oncol; 2022 Mar; 23(3):382-392. PubMed ID: 35123662
[TBL] [Abstract][Full Text] [Related]
18. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
Gnant M; Sestak I; Filipits M; Dowsett M; Balic M; Lopez-Knowles E; Greil R; Dubsky P; Stoeger H; Rudas M; Jakesz R; Ferree S; Cowens JW; Nielsen T; Schaper C; Fesl C; Cuzick J
Ann Oncol; 2015 Aug; 26(8):1685-91. PubMed ID: 25935792
[TBL] [Abstract][Full Text] [Related]
19. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.
Nuzzo F; Gallo C; Lastoria S; Di Maio M; Piccirillo MC; Gravina A; Landi G; Rossi E; Pacilio C; Labonia V; Di Rella F; Bartiromo A; Buonfanti G; De Feo G; Esposito G; D'Aniello R; Maiolino P; Signoriello S; De Maio E; Tinessa V; Colantuoni G; De Laurentiis M; D'Aiuto M; Di Bonito M; Botti G; Giordano P; Daniele G; Morabito A; Normanno N; de Matteis A; Perrone F
Ann Oncol; 2012 Aug; 23(8):2027-2033. PubMed ID: 22412041
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis.
Yu Z; Guo X; Jiang Y; Teng L; Luo J; Wang P; Liang Y; Zhang H
Breast Cancer; 2018 Jan; 25(1):8-16. PubMed ID: 28755088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
